Evidence analysisNovember 17, 2026Health & Science

Human medicines European public assessment report (EPAR): Kyinsu, insulin icodec,semaglutide, Date of authorisation: 24/11/2025, Revision: 1, Status: Authorised

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

What is established

Kyinsu is a newly authorized medication in the European Union for treating type 2 diabetes in adults whose condition is inadequately controlled with basal insulin or GLP-1 receptor agonists. It contains two active components: insulin icodec, a long-acting insulin analogue, and semaglutide, a GLP-1 receptor agonist. Kyinsu is administered as a once-weekly subcutaneous injection and requires careful dose adjustment guided by medical supervision.

Clinical studies involving over 2,600 patients demonstrated that Kyinsu effectively improves blood glucose control, as measured primarily by reductions in HbA1c levels. Evidence shows that compared to treatment with either insulin icodec or semaglutide alone, Kyinsu offers superior HbA1c reduction, with additional effects on patient weight varying by prior treatment. The medication also has known safety profiles similar to its individual components, including risks of hypoglycaemia and gastrointestinal side effects.

What the source claims

  • Treatment indication: Kyinsu is approved for adults with type 2 diabetes insufficiently controlled by basal insulin or GLP-1 receptor agonists.
  • Administration: The drug is delivered via a once-weekly prefilled pen injection under the skin, with patients able to self-inject after proper training. Previous insulin or GLP-1 receptor agonist treatments must be stopped before starting Kyinsu.
  • Mechanism of action: Insulin icodec mimics natural insulin with a prolonged duration of effect, while semaglutide mimics the gut hormone GLP-1 to stimulate insulin release after meals.
  • Efficacy: In three main clinical trials:
    • Study 1 (n=1,291): Kyinsu showed a 1.55 percentage point reduction in HbA1c versus 0.89 with insulin icodec; also associated with weight loss.
    • Study 2 (n=683): Kyinsu yielded a 1.35 percentage point HbA1c reduction versus 0.90 with semaglutide; patients on Kyinsu gained weight, whereas those on semaglutide lost weight.
    • Study 3 (n=679): Kyinsu reduced HbA1c by 1.47 percentage points compared to 1.40 with insulin glargine and insulin aspart; associated with weight loss.
  • Safety: The most common side effects include hypoglycaemia and gastrointestinal issues such as nausea and diarrhea.
  • Regulatory decision: The European Medicines Agency (EMA) assessed that Kyinsu’s benefits outweigh its risks and authorized it for use in the EU on November 24, 2025.
  • Risk mitigation: Measures include educational materials to reduce medication errors and guidance in product leaflets for safe use.

What may be missing from the usual framing

The provided information emphasizes Kyinsu’s improved glycemic control and convenience from combining two agents into a single weekly injection. However, some aspects that may require further elaboration or are absent from the summary include:

  • Long-term safety data: While side effects are described as consistent with known profiles of each component, the document does not detail long-term adverse outcomes or rare risks associated with the combination.
  • Weight dynamics complexity: The contrasting weight effects observed in patients switching from GLP-1 receptor agonists (weight gain with Kyinsu) versus insulin therapy (weight loss with Kyinsu) merit deeper clinical explanation.
  • Patient adherence and quality of life impacts: Although increased convenience is suggested, actual real-world adherence data and patient-reported outcomes are not discussed.
  • Economic considerations: Information on cost, reimbursement, and comparative cost-effectiveness is missing, despite relevance to access and healthcare system decisions.

Competing evidence or uncertainty

The EMA’s authorization is based on three large clinical trials showing superior HbA1c reduction with Kyinsu versus monotherapy comparators. Nevertheless, several uncertainties remain:

  • Weight impact paradox: Patients uncontrolled on prior GLP-1 receptor agonists gained weight when switched to Kyinsu, whereas those previously on basal insulin lost weight. This suggests the weight effects may depend on prior treatment context, indicating complex metabolic dynamics not fully understood.
  • Hypoglycaemia risk: Hypoglycaemia incidence was reported as common. Quantitative comparison of hypoglycaemia rates versus standard treatments would clarify risk magnitude, but this information is not detailed.
  • Real-world effectiveness: Trial populations and controlled settings may not fully represent the diversity of patients in clinical practice, potentially affecting generalizability.
  • Long-term cardiovascular and renal outcomes: The dossier does not present data on effects of Kyinsu on cardiovascular events or kidney function, which are critical risks in type 2 diabetes management.

Why it matters

Type 2 diabetes is a highly prevalent chronic disease characterized by impaired blood glucose regulation, often requiring complex pharmacological regimens to avoid severe complications. The introduction of Kyinsu, a fixed combination of once-weekly ultra-long-acting insulin icodec and a GLP-1 receptor agonist semaglutide, offers potentially improved glycaemic control with a simplified dosing schedule.

This could enhance treatment adherence, simplify management, and improve patient outcomes for those inadequately controlled on basal insulin or GLP-1 monotherapy. However, balancing glycaemic control benefits with risks of hypoglycaemia, gastrointestinal effects, and weight changes is essential. The option to substitute two separate injections with a single combined preparation may reduce injection burden, a significant factor influencing patient willingness to maintain therapy.

From a public health perspective, effective diabetes control reduces complications such as cardiovascular disease, kidney failure, and neuropathy, potentially lowering healthcare costs and improving quality of life.

What to verify next

  • The long-term safety profile of Kyinsu beyond one year, particularly concerning cardiovascular, renal, and pancreatic outcomes.
  • Detailed hypoglycaemia event rates compared to individual components and alternative regimens.
  • Real-world adherence and patient quality of life data to assess the practical benefits of once-weekly administration.
  • Further clinical investigation into weight changes relative to previous diabetes treatments and the underlying physiological mechanisms.
  • Cost, accessibility, and reimbursement status, including comparisons to other combination therapies or standard care.

Readers are encouraged to consult the original European Medicines Agency public assessment report on Kyinsu for full details and updates.

Source & verification

Primary source: What's new · November 16, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…